Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

323.46 -5.76 (-1.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022
From Insulet Corporation
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Insulet Stock Is Skyrocketing Today
Investors are cheering the company's strong Q3 results. 
Via The Motley Fool
Insulet Shares Jump After Q3 Earnings Surpass Expectations, Improved Annual Guidance
 
Via Benzinga
FDA Approves Insulet's Omnipod Automated Insulin System For Patients Two Years & Above
 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
What 8 Analyst Ratings Have To Say About Insulet
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter: 
Via Benzinga
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
What 5 Analyst Ratings Have To Say About Insulet
Over the past 3 months, 5 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) shares moved upwards by 30.7% to $5.19 during Friday's pre-market session. The market value of their outstanding shares is at $316.2 million. 
Via Benzinga
Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket
Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday. 
Via Benzinga
Coinbase, DoorDash And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout November
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Insulet
Over the past 3 months, 6 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022
From Insulet Corporation
Via Business Wire
Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System
From Insulet Corporation
Via Business Wire
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
A Bullish Sign Appears On Insulet's Chart
If history is any guide, there may be good fortune ahead for shares of Insulet (NASDAQ:PODD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
$1000 Invested In Insulet 5 Years Ago Would Be Worth This Much Today
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.25% on an annualized basis producing an average annual return of 35.42%. Currently, Insulet has a market capitalization of... 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report 
Via Benzinga
FDA Clears Insulet's Omnipod 5 Automated Insulin Delivery System For Preschool Children
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ: PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with... 
Via Benzinga
Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Recap: Insulet Q2 Earnings
Insulet (NASDAQ:PODD) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Insulet missed estimated earnings by... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.